Nvwm LLC Acquires 31,854 Shares of Merck & Co., Inc. $MRK

Nvwm LLC grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 2,930.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,941 shares of the company’s stock after acquiring an additional 31,854 shares during the period. Nvwm LLC’s holdings in Merck & Co., Inc. were worth $3,467,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Chemung Canal Trust Co. increased its position in shares of Merck & Co., Inc. by 21.1% during the third quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock valued at $6,407,000 after buying an additional 13,285 shares during the period. First Pacific Financial boosted its position in shares of Merck & Co., Inc. by 14.7% in the third quarter. First Pacific Financial now owns 47,555 shares of the company’s stock valued at $3,991,000 after acquiring an additional 6,082 shares during the period. Diversified Trust Co boosted its position in shares of Merck & Co., Inc. by 9.6% in the third quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock valued at $17,444,000 after acquiring an additional 18,187 shares during the period. Caxton Associates LLP grew its stake in Merck & Co., Inc. by 23.3% during the second quarter. Caxton Associates LLP now owns 39,421 shares of the company’s stock valued at $3,121,000 after acquiring an additional 7,458 shares in the last quarter. Finally, Coldstream Capital Management Inc. grew its stake in Merck & Co., Inc. by 12.7% during the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock valued at $10,364,000 after acquiring an additional 13,940 shares in the last quarter. 76.07% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of analyst reports. Bank of America upped their target price on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Wells Fargo & Company boosted their price target on shares of Merck & Co., Inc. from $135.00 to $150.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. UBS Group upped their price target on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. Finally, Citigroup lifted their price objective on Merck & Co., Inc. from $120.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, March 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average target price of $127.13.

Merck & Co., Inc. Trading Down 0.2%

Shares of MRK opened at $120.62 on Friday. The firm’s 50 day simple moving average is $117.72 and its 200 day simple moving average is $103.23. The company has a market capitalization of $298.21 billion, a P/E ratio of 16.57, a P/E/G ratio of 2.44 and a beta of 0.26. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. During the same quarter in the previous year, the company earned $1.72 EPS. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s payout ratio is currently 46.70%.

Insider Buying and Selling

In related news, CMO Chirfi Guindo sold 20,000 shares of the company’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total value of $2,437,600.00. Following the completion of the transaction, the chief marketing officer directly owned 80,615 shares in the company, valued at approximately $9,825,356.20. The trade was a 19.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Richard R. Deluca sold 37,685 shares of the stock in a transaction on Friday, February 6th. The shares were sold at an average price of $120.92, for a total value of $4,556,870.20. Following the completion of the transaction, the executive vice president directly owned 160,174 shares in the company, valued at approximately $19,368,240.08. This represents a 19.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 320,176 shares of company stock valued at $38,281,735 in the last three months. 0.13% of the stock is owned by corporate insiders.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: EU approval expands KEYTRUDA use to PD?L1 positive, platinum?resistant ovarian cancer — opens a new commercial indication in Europe for an established franchise, which can drive incremental revenue and utilization in a high?unmet?need setting. Merck Broadens Cancer And Eye Disease Pipeline As Investors Weigh Future Growth
• Positive Sentiment: Merck initiated a pivotal Phase 2b/3 trial of MK?8748 (Tiespectus) for wet AMD — a promising ophthalmology program that, if successful, adds a non?oncology growth vector and diversifies long?term revenue streams. Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus)
• Positive Sentiment: Positive Phase 3 CORALreef results for oral PCSK9 inhibitor (enlicitide decanoate) — if approved, an oral PCSK9 could be a major commercial opportunity in cardiovascular prevention and complement existing lipid therapies. Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Detailed Phase 2 CADENCE data for WINREVAIR released — adds evidence to a respiratory program that management can highlight to investors as part of a broader R&D pipeline story. Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck KGaA acquisition of JSR chromatography business noted in the press — this concerns Merck KGaA (a different company) and is unlikely to meaningfully affect Merck & Co.’s (MRK) near?term fundamentals. Merck KGaA acquires JSR chromatography
• Negative Sentiment: New proposal from former President Trump to impose up to 100% tariffs on imported medicines (with carve?outs) increases regulatory and pricing uncertainty for the sector; even with exemptions, the proposal raises near?term headline risk and could pressure sentiment toward large pharma names like MRK until policy clarity emerges. Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions
• Negative Sentiment: Sector policy debate over drug?pricing deals continues (Lilly warns against locking pricing deals into law) — ongoing political scrutiny increases the chance of policy actions that could cap pricing or change reimbursement, a headwind for long?term margin visibility. Lilly Pushes Back on Making Drug Price Deals Permanent

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.